866-997-4948(US-Canada Toll Free)

Vaginal Cancer - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 92 Pages

Vaginal Cancer - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Pipeline Review, H2 2017, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.

Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 4, 1 and 1 respectively.

Vaginal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Vaginal Cancer - Overview 5
Vaginal Cancer - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Vaginal Cancer - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 11
Assessment by Route of Administration 13
Assessment by Molecule Type 15
Vaginal Cancer - Companies Involved in Therapeutics Development 17
ISA Pharmaceuticals BV 17
MedImmune LLC 17
Ology Bioservices Inc 17
Ono Pharmaceutical Co Ltd 18
Oryx GmbH & Co KG 18
Taiwan Liposome Company Ltd 19
Vaginal Cancer - Drug Profiles 20
durvalumab + tremelimumab - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
ISA-101 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
nivolumab - Drug Profile 32
R&D Progress 33
NTO-1151 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
TLC-388 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
Vicoryx - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Vaginal Cancer - Dormant Projects 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 91
Disclaimer 92

List of Tables
Number of Products under Development for Vaginal Cancer, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 10
Number of Products by Stage and Mechanism of Action, H2 2017 12
Number of Products by Stage and Route of Administration, H2 2017 14
Number of Products by Stage and Molecule Type, H2 2017 16
Vaginal Cancer - Pipeline by ISA Pharmaceuticals BV, H2 2017 17
Vaginal Cancer - Pipeline by MedImmune LLC, H2 2017 17
Vaginal Cancer - Pipeline by Ology Bioservices Inc, H2 2017 18
Vaginal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 18
Vaginal Cancer - Pipeline by Oryx GmbH & Co KG, H2 2017 18
Vaginal Cancer - Pipeline by Taiwan Liposome Company Ltd, H2 2017 19
Vaginal Cancer - Dormant Projects, H2 2017 90

List of Figures
Number of Products under Development for Vaginal Cancer, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products by Targets, H2 2017 9
Number of Products by Stage and Targets, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Routes of Administration, H2 2017 13
Number of Products by Stage and Routes of Administration, H2 2017 13
Number of Products by Molecule Types, H2 2017 15
Number of Products by Stage and Molecule Types, H2 2017 15

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *